Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.

5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.

Finasteride may help prevent prostate cancer.

5-alpha reductase inhibitors do not increase hip fracture risk.

New compounds were made that are promising for prostate cancer therapy.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.

5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

New compounds may help treat prostate cancer by reducing cell growth.

Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.